In furtherance to the clarification sought by the exchange with regard to the OCR readable format of the financial results, Onesource Specialty Pharma Limited has submitted the OCR Readable financial results for the quarter and year ended March 31, 2026

OneSource Specialty Pharma reported revenue from operations of Rs 14,053.81 million for FY26, up 8.1% from Rs 12,995.89 million in FY25. The company posted profit after tax of Rs 212.10 million compared to Rs 200 million in the prior year, though profit before tax was Rs 212.10 million versus a loss of Rs 214.55 million in FY25 due to exceptional items in the prior year. The auditor Deloitte Haskins & Sells issued an unqualified opinion on the annual results and a clean conclusion on the quarterly results. Total assets stood at Rs 82,760.59 million with total equity of Rs 59,502.22 million. Key balance sheet changes include increased borrowings (non-current up from Rs 2,193 million to Rs 5,637 million), higher inventories (Rs 4,390 million vs Rs 1,534 million), and increased capital work in progress (Rs 3,139 million vs Rs 604 million).